Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 2
2007 2
2009 2
2010 2
2011 2
2012 7
2013 9
2014 11
2015 8
2016 9
2017 10
2018 10
2019 11
2020 11
2021 12
2022 5
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Mahmood SS, et al. Among authors: lawrence dp. J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19. J Am Coll Cardiol. 2018. PMID: 29567210 Free PMC article.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Herbst RS, et al. Among authors: lawrence dp. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. Nature. 2014. PMID: 25428504 Free PMC article. Clinical Trial.
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, Sahu A, Mei S, Miao B, Sharova T, Alvarez-Breckenridge C, Stocking JH, Kim T, Fadden R, Lawrence D, Hoang MP, Cahill DP, Malehmir M, Nowak MA, Brastianos PK, Lian CG, Ruppin E, Izar B, Herlyn M, Van Allen EM, Nathanson K, Flaherty KT, Sullivan RJ, Kellis M, Sorger PK, Boland GM. Liu D, et al. Among authors: lawrence d. Nat Med. 2021 Jun;27(6):985-992. doi: 10.1038/s41591-021-01331-8. Epub 2021 May 3. Nat Med. 2021. PMID: 33941922 Free PMC article.
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist RS, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Bent B, de Sauvage MA, Ijad N, Larson JM, Marion B, Nason S, Murthy N, Ratcliff S, Summers EJ, Mahar M, Shih HA, Oh K, Cahill DP, Gerstner ER, Sullivan RJ. Brastianos PK, et al. Among authors: lawrence d. Nat Med. 2023 Jul;29(7):1728-1737. doi: 10.1038/s41591-023-02392-7. Epub 2023 Jun 2. Nat Med. 2023. PMID: 37268724 Free PMC article. Clinical Trial.
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Revach OY, Cicerchia AM, Shorer O, Petrova B, Anderson S, Park J, Chen L, Mehta A, Wright SJ, McNamee N, Tal-Mason A, Cattaneo G, Tiwari P, Xie H, Sweere JM, Cheng LC, Sigal N, Enrico E, Miljkovic M, Evans SA, Nguyen N, Whidden ME, Srinivasan R, Spitzer MH, Sun Y, Sharova T, Lawless AR, Michaud WA, Rasmussen MQ, Fang J, Palin CA, Chen F, Wang X, Ferrone CR, Lawrence DP, Sullivan RJ, Liu D, Sachdeva UM, Sen DR, Flaherty KT, Manguso RT, Bod L, Kellis M, Boland GM, Yizhak K, Yang J, Kanarek N, Sade-Feldman M, Hacohen N, Jenkins RW. Revach OY, et al. Among authors: lawrence dp. bioRxiv [Preprint]. 2024 Mar 26:2024.02.12.579184. doi: 10.1101/2024.02.12.579184. bioRxiv. 2024. PMID: 38405985 Free PMC article. Preprint.
Identification of fusions with potential clinical significance in melanoma.
Moran JMT, Le LP, Nardi V, Golas J, Farahani AA, Signorelli S, Onozato ML, Foreman RK, Duncan LM, Lawrence DP, Lennerz JK, Dias-Santagata D, Hoang MP. Moran JMT, et al. Among authors: lawrence dp. Mod Pathol. 2022 Dec;35(12):1837-1847. doi: 10.1038/s41379-022-01138-z. Epub 2022 Jul 23. Mod Pathol. 2022. PMID: 35871080 Free article.
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Brastianos PK, et al. Among authors: lawrence d. Nat Med. 2020 Aug;26(8):1280-1284. doi: 10.1038/s41591-020-0918-0. Epub 2020 Jun 2. Nat Med. 2020. PMID: 32483359 Clinical Trial.
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy.
Kim AE, Lou KW, Giobbie-Hurder A, Chang K, Gidwani M, Hoebel K, Patel JB, Cleveland MC, Singh P, Bridge CP, Ahmed SR, Bearce BA, Liu W, Fuster-Garcia E, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist R, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Perrino CM, Summers EJ, Mahar M, Oh K, Shih HA, Cahill DP, Rosen BR, Yen YF, Kalpathy-Cramer J, Martinez-Lage M, Sullivan RJ, Brastianos PK, Emblem KE, Gerstner ER. Kim AE, et al. Among authors: lawrence d. bioRxiv [Preprint]. 2023 Aug 28:2023.08.25.554868. doi: 10.1101/2023.08.25.554868. bioRxiv. 2023. PMID: 37693537 Free PMC article. Preprint.
Sinonasal Mucosal Melanoma: An Update and Review of the Literature.
Salari B, Foreman RK, Emerick KS, Lawrence DP, Duncan LM. Salari B, et al. Among authors: lawrence dp. Am J Dermatopathol. 2022 Jun 1;44(6):424-432. doi: 10.1097/DAD.0000000000002157. Epub 2022 Mar 22. Am J Dermatopathol. 2022. PMID: 35315370 Review.
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N. Freeman SS, et al. Among authors: lawrence dp. Cell Rep Med. 2022 Feb 15;3(2):100500. doi: 10.1016/j.xcrm.2021.100500. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35243413 Free PMC article.
115 results